N-(1-adamantyl)-2-methylpropanamide | 19026-81-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(1-adamantyl)-2-methylpropanamide
• 英文别名: N-(1-Adamantyl)isobutyramid
• CAS: 19026-81-4
• 化学式: C₁₄H₂₃NO
• 分子量: 221.343
• InChiKey: SZDKRLQQAFPJPC-UHFFFAOYSA-N

物化性质

• 沸点：
  372.3±9.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.928
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异丁腈 、 金刚烷 在 三氯化铝 作用下， 以 氯仿 为溶剂， 以56%的产率得到N-(1-adamantyl)-2-methylpropanamide
  参考文献：
  名称：

  Aluminum Chloride/Dichloromethane (Chloroform) Induced Carbonylation, Ritter Reaction, and Cyanation of Adamantane

  摘要：

  报道了在二氯甲烷（氯仿）中，由氯化铝引发的金刚烷的羰基化、Ritter反应和氰化反应。涉及的反应机理讨论了最初从金刚烷中提取氢化物（通过形成氯甲烷或二氯甲烷表示），随后1-金刚烷基阳离子与一氧化碳、腈或氰基三甲基硅烷的反应。

  DOI：

  10.1055/s-1992-26311

文献信息

• BACH R. D.; HOLUBKA J. W.; TAAFFEE T. A., J. ORG. CHEM., 1979, 44, NO 10, 1739-1740
  作者：BACH R. D.、 HOLUBKA J. W.、 TAAFFEE T. A.

  DOI：——

  日期：——
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Ogawa Tomoyuki

  公开号：US20090131491A1

  公开（公告）日：2009-05-21

  Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is a group of the formula: —C(═O)NR 4 R 5 , (wherein R 4 and R 5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: —NR 6 C(═O)R 7 , (wherein R 6 and R 7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently —O— or the like, Z is a bond or the like, R 2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R 3 is optionally substituted alkyl, optionally substituted alkenyl or the like.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：Ogawa Tomoyuki

  公开号：US20100197662A1

  公开（公告）日：2010-08-05

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted cycloalkyl, optionally substituted cycloalkenyl or the like, One of R 2 and R 3 is a group of the formula: —C(═O)—Y—R 4 , wherein Y is —NR 9 — or the like, R 4 is optionally substituted cycloalkyl or the like, R 9 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, The other is a group of the formula: —V—R 5 , wherein V is a bond, —O— or the like, R 6 is hydrogen or optionally substituted alkyl, R 5 is hydrogen, optionally substituted alkyl or the like, X is a bond, —S—, —SO— or the like, U is a bond or optionally substituted alkylene, R 7 is hydrogen or optionally substituted alkyl, Z is —S—, —O— or —NR 8 —, R 8 is hydrogen, optionally substituted alkyl or the like.